Abstract, an Ethereum layer-2 network by Igloo Inc., will shut down on December 15 due to limited DeFi activity, low liquidity, and budget constraints. Users need to transfer their assets before the deadline via Abstract's Migration Hub or native bridge, or risk losing access. Despite processing over 325 million transactions and hosting brands like Red Bull Racing and Disney, Abstract couldn't sustain itself as a consumer-focused crypto platform. This follows another recent Ethereum layer-2 shutdown by Blast, highlighting challenges in the sector.
The Ethereum layer-2 network Abstract's shutdown news comes as a backdrop to today's broader cryptocurrency market activity on Pluang. For readers following major cryptocurrencies, here is Pluang's market snapshot as of Oct 07, 2026 03:33 WIB: out of 50 major cryptocurrencies, 12 rose and 37 fell. Notable movers include Kusama (KSM) at Rp88.303 with a 4.86% decline and a typical hold time of 80 days, Avalanche (AVAX) at Rp204.684 with a 4.69% gain and 65% buy order activity, and The Sandbox (SAND) at Rp1.185 down 4.00% with a 123-day hold time.
Corxel Pharmaceuticals US and Amanat Acquisition Corp have agreed to merge, creating a publicly traded biopharmaceutical company focused on oral obesity treatments. The deal will raise approximately $377 million, including $300 million from private i...
Eikon Therapeutics presented updated data on EIK1001, a TLR7/8 dual-agonist, combined with pembrolizumab and chemotherapy for stage 4 non-small cell lung cancer (NSCLC) at the 2026 ESMO Congress. The treatment showed a 72% objective response rate and...
Microsoft, Alphabet, and Amazon together represent about 15% of the S&P 500 index. All three tech giants are scheduled to report their quarterly earnings within a two-day span. These earnings reports are highly anticipated as they provide insight int...
Conow, in partnership with Tuya Smart, has introduced the Atlas 6000 AC in Germany, a 6 kWh AC-coupled plug-and-play home battery designed to upgrade existing rooftop solar systems. This battery features AI-driven energy management that optimizes hou...
BioNTech and DualityBio announced that their Phase-3 clinical trial DYNASTY-Breast02 met its primary endpoint, demonstrating a statistically significant but moderate improvement in progression-free survival for Trastuzumab Pamirtecan compared to chem...
